Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conferences:

Conference Years:

Days Within Meeting:

Has CME:

Do I Have Access?

Access:

Availability:

Participation Type:

Categories:

Browse by: Sort by:
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 25 of 43
Immunotherapy: How Does It Work?
Bryan Haugen, MD
University of Colorado School of Medicine, Aurora, CO
from ENDO 2021 on March 20, 2021 11:00 AM-12:30 PM
Immunotherapy: Does it Work?
Camilo Jimenez, MD
University of Texas MD Anderson Cancer Center, Houston, TX
from ENDO 2021 on March 20, 2021 11:00 AM-12:30 PM
Immunotherapy: Does it Hurt?
Carla Moran, MB, PhD
Beacon Hospital, Dublin, Ireland
from ENDO 2021 on March 20, 2021 11:00 AM-12:30 PM
Quieting the Estrogen Receptor for Therapeutic Benefit in ER+ Breast Cancer
Ciara Metcalfe, PhD
Genentech, Inc, South San Francisco, CA
from ENDO 2021 on March 20, 2021 11:00 AM-12:30 PM
Molecular Subtypes of Prostate Cancer
Christopher Barbieri, MD, PhD
Weill Cornell Medicine, New York, NY
from ENDO 2021 on March 20, 2021 11:00 AM-12:30 PM
WNT/Beta-Catenin Signaling in Prostate Cancer
Susan Logan, PhD
New York University Langone Medical Center, New York, NY
from ENDO 2021 on March 20, 2021 11:00 AM-12:30 PM
Exploiting How Membrane Receptors Signal Inside Cells: Example of c-MET
St├ęphanie Kermorgant, PhD
Barts Cancer Institute, Queen Mary University London, London, United Kingdom
from ENDO 2021 on March 20, 2021 11:00 AM-12:30 PM
Abstract Presentation: Steroid Receptor Co-Activators Regulate Metabolic Kinases to Drive Therapy Resistant ER+ Breast Cancer
Thu Truong, PhD
University of Minnesota, Minneapolis, MN
from ENDO 2021 on March 20, 2021 11:00 AM-12:30 PM
Targeting the Sodium Iodide Symporter to Increase RAI Uptake
Christopher McCabe, PhD
University of Birmingham, Birmingham, United Kingdom
from ENDO 2021 on March 20, 2021 11:00 AM-12:30 PM
Developing Novel Combination Therapies for Medullary Thyroid Cancer
Rozita Bagheri-Yarmand, PhD
University of Texas MD Anderson Cancer Center, Houston, TX
from ENDO 2021 on March 20, 2021 11:00 AM-12:30 PM
Genetic Determinants Underlying Radioiodine Refractory Thyroid Cancer
Sissy Jhiang, PhD
The Ohio State University Medical Center, Columbus, OH
from ENDO 2021 on March 20, 2021 11:00 AM-12:30 PM
Abstract Presentation: Aggressive Thyroid Cancer is Associated With Suppressor Circulating Immunophenotype
Anupam Kotwal, MD
Univ. of Nebraska Medical Center, Omaha, NE
from ENDO 2021 on March 20, 2021 11:00 AM-12:30 PM
Chair
Patricia Dahia, MD, PhD
University of Texas Health Science Center at San Antonio, San Antonio, TX
Chair
Mimi Hu, MD
University of Texas MD Anderson Cancer Center, Houston, TX
Welcome and Introductions
Molecular and Clinical Facets of Parathyroid Cancer
William Simonds, MD
National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
Live Moderated Q&A
Proteomics and Medullary Thyroid Cancer
Wayne Miles, PhD
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Live Moderated Q&A
Molecular Targeted Therapy for the Treatment of Thyroid Neoplasia and Cancer
Marcia Brose, MD, PhD
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Live Moderated Q&A and Session Closing
from ENDO 2021 on March 20, 2021 12:30 PM-2:00 PM
Chair
Rebecca Riggins, PhD
Georgetown University, Washington, DC
Pro-Tumorigenic Role of Neutrophil Elastase in Lymphangioleiomyomatosis (LAM)
Erin Gibbons, MS
UNIVERSITY OF ROCHESTER, Rochester, NY
Audience Q&A
Thyroid Hormone and Estrogen Promote Endocrine Resistance, Proliferation, Dedifferentiation, and Cancer Stem Cells in Steroid Receptor-Positive Breast Cancers
Reema Wahdan-Alaswad, PhD, MS
University of Colorado Anschutz Medical Campus, Aurora, CO
Audience Q&A
ERa-Dependent Lethal Hyperactivation of the Anticipatory Unfolded Protein Response Induces Complete Regression Without Recurrence of Advanced Breast Cancer
Darjan Duraki, BS Biochemistry
University of Illinois at Urbana-Champaign, Urbana, IL
Audience Q&A
Identification of Genes and Pathways Differentially Expressed in Progestin Responsive Endometrial Cancer and Hyperplasia
Jay Gertz, PhD
University of Utah, SALT LAKE CITY, UT
Audience Q&A
from ENDO 2021 on March 21, 2021 2:00 PM-3:00 PM
Chair
Elaine Alarid, PhD
University of Wisconsin - Madison, Madison, WI
Welcome and Introductions
Androgen Receptor Enhancers in Control of Prostate Cancer Development and Progression
Wilbert Zwart, PhD
Netherlands Cancer Institute, Amsterdam, Netherlands
Live Moderated Q&A
Tumor Cell Total mRNA Expression Shapes the Molecular and Clinical Phenotype of Cancer
Wenyi Wang, PhD
The University of Texas MD Anderson, Houston, TX
Live Moderated Q&A
from ENDO 2021 on March 22, 2021 3:15 PM-4:45 PM
Aggressive Pituitary Tumors and Carcinomas: Two Sides of the Same Coin?
Jacqueline Trouillas, MD, PhD
University of Lyon, Lyon, France
from ENDO 2019 on March 23, 2019 4:15 PM-5:45 PM
Treatment of Aggressive Pituitary Tumors and Carcinomas
Ann I McCormack, MD, PhD
St. Vincent's Hospital, Sydney, Australia
from ENDO 2019 on March 23, 2019 4:15 PM-5:45 PM
Molecular Underpinnings of the Aggressive Pituitary Tumor
Gerald Raverot, MD, PhD
Hospices Civils de Lyon, Lyon Cedex 03, France
from ENDO 2019 on March 23, 2019 4:15 PM-5:45 PM
Thyroid Cancer Genetics and Implications for Therapy
Nikita Pozdeyev, MD, PhD
University of Colorado, Aurora, CO
from ENDO 2019 on March 25, 2019 9:15 AM-10:45 AM
A Glimmer of Hope: Novel Combination Therapy for the Treatment of Anaplastic Thyroid Cancer

Maria E Cabanillas, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
from ENDO 2019 on March 25, 2019 9:15 AM-10:45 AM
Super-Enhancer Targeting in Advanced Thyroid Cancers
Matthew D Ringel, MD
The Ohio State University, Columbus, OH
from ENDO 2019 on March 25, 2019 9:15 AM-10:45 AM
Questions and Answers
Mabel M Ryder, MD
Mayo Clinic, Rochester, MN, United States
Nikita Pozdeyev, MD, PhD
University of Colorado, Aurora, CO
Maria E Cabanillas, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Matthew D Ringel, MD
The Ohio State University, Columbus, OH
from ENDO 2019 on March 25, 2019 9:15 AM-10:45 AM
Application of New Adrenal Cancer Models to Screen Therapeutics
Katja Kiseljak-Vassiliades, DO
University of Colorado, Denver, Aurora, CO
from ENDO 2019 on March 25, 2019 9:15 AM-10:45 AM
New In Vitro Models for Studying Human Adreno-Cortical Cancer (ACC)
Leo J Hofland, PHD
Erasmus Medical Center, Rotterdam, Netherlands
from ENDO 2019 on March 25, 2019 9:15 AM-10:45 AM
Mouse Models of Adrenal Tumors
Pierre Val, PhD
National Center for Scientific Research, Clermont-Ferrand, France
from ENDO 2019 on March 25, 2019 9:15 AM-10:45 AM
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 25 of 43